Trial Profile
Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary) ; Dipeptidyl peptidase 4 inhibitors
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 25 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jan 2014 Planned End Date changed from 1 Nov 2013 to 1 Mar 2014 as reported by the ClinicalTrials.gov record.
- 23 Aug 2013 New source identified and integrated (United Kingdom Clinical Research Network record: 14977)